Latest Silence Therapeutics plc Stories
LONDON, November 5, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading RNA interference (RNAi) therapeutics company, today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance indicating that it will grant patents based on two applications: 12/986,389 and 13/230,084. These cover respectively interfering RNA molecules and lipid complexes used in drug delivery. The claims allowed on interfering RNA molecules cover any...
LONDON, October 15, 2012 /PRNewswire/ -- Silence Therapeutics plc has appointed Tim Freeborn, 53, as its finance director. A chartered accountant, he joined the company from Xcap Securities where he was head of research. Tim Freeborn said: 'Silence's area of biotech is moving incredibly quickly. The company could play a big role and I'm delighted to be joining at this time.' No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules....
LONDON, September 25, 2012 /PRNewswire/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2012. Ali Mortazavi, Director of Corporate Strategy, said: "These results, including the writedown of our Intradigm investment, mark the end of a very difficult period for Silence Therapeutics. However, post this period, the Company has been...
LONDON, September 18, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Michael Khan to its board of directors as Chief Medical Adviser. Dr Michael Khan BSc, MBBS, PhD, FRCP is an Associate Professor of Medicine at the University of Warwick and a Consultant Physician at University Hospitals. He trained in medicine at Guy's and King's in London and completed...
LONDON, September 10, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury. Atu111 targets the endothelial expression of Angiopoietin-2 (Ang-2), an antagonistic...
LONDON, August 2, 2012 /PRNewswire/ -- Silence Therapeutics plc [http://silence-therapeutics.com ] (AIM: SLN) ("Silence" or "the Company"), a leading RNA [http://silence-therapeutics.com/content/therapeuticplatform/overview.htm ] interference (RNAi) therapeutics company, announces that the New Shares issued in connection with the Subscription, Open Offer and Convertible Loan Note have today been admitted to trading on AIM. In addition, as set out in the Circular to...
LONDON, July 12, 2012 /PRNewswire/ -- THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR...
LONDON, June 6, 2012 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference [http://silence-therapeutics.com/platform-technologies/rna-interference ] (RNAi) therapeutics company, on Monday presented the latest data from its ongoing Phase I study of Atu027, its lead internal therapeutics candidate, alongside the 2012 American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois. At...
LONDON, May 17, 2012 /PRNewswire/ -- - Atu027, a First in Class RNAi Therapy, Demonstrates Potential - Antitumour Activity in Cancer Patients and Possible Biomarker Identified Silence Therapeutics to Announce New Data from Phase I Study of Atu027 in Solid Tumours At 2012 ASCO Annual Meeting Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics...
LONDON, March 21, 2012 /PRNewswire/ -- Silence Therapeutics Plc [http://silence-therapeutics.com ] (AIM: SLN), a leading international RNAi therapeutics company [http://silence-therapeutics.com/pipeline/clinical-programs/#!/about-us ], today announces its unaudited preliminary results for the year ended 31 December 2011. HIGHLIGHTS - Impressive interim data from Phase I trials of Atu027 (lead programme in metastatic cancer) presented at...
